Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
Not yet recruiting · NCT05909098 · Registry updated 2023-06-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma | B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory; NK Cell | Not yet recruiting | Phase 1 / Phase 2 | 2023-06-22 | NCT05909098 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qingdao Haier Biotechnology Co.,Ltd. | 1 |
| Xiangyang No.1 People's Hospital | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| EC of Xiangyang No.1 People's Hospital Hubei University of Medicine | Hubei | China | 1 |